The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (T...
Saved in:
Published in | Neurotherapeutics Vol. 15; no. 2; pp. 324 - 335 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Cham
Elsevier Inc
01.04.2018
Springer International Publishing Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1878-7479 1933-7213 1878-7479 |
DOI | 10.1007/s13311-018-0622-7 |
Cover
Abstract | Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood–brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease. |
---|---|
AbstractList | Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood–brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease. Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood-brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood-brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease. Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood–brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease. |
Author | Raffaelli, Bianca Reuter, Uwe |
Author_xml | – sequence: 1 givenname: Bianca surname: Raffaelli fullname: Raffaelli, Bianca organization: Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany – sequence: 2 givenname: Uwe orcidid: 0000-0002-8527-0725 surname: Reuter fullname: Reuter, Uwe email: uwe.reuter@charite.de organization: Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29616494$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1u1DAUhSNURH_gAdggS2zYBPwTxzELpDJqC1IrKlTWlse5mXHx2MFOivL29SgDLV2MWMVSvu_6-Nzj4sAHD0XxmuD3BGPxIRHGCCkxaUpcU1qKZ8URaURTikrIg0fnw-I4pVuMOWOyeVEcUlmTupLVUdHfrAF9tsGF1YRCh66CD8YFrx069YNdhtZC-ojOgxkTCh4ttDN2CN56dAEeyu_g9AAtuoZ-sC2gLkR0HUO_npw2gzXoyq6ith5QvijqfnpZPO-0S_Bq9z0pfpyf3Sy-lJffLr4uTi9Lw6t6KGXHqSY1I83SYCoFSMkEM0ANqXjVckGXYISsOgZ1yxvaci6xrDUzXc0o1-ykoPPc0fd6-q2dU320Gx0nRbDa1qfm-lSuT23rUyJLn2apH5cbaA34IeoHMWir_v3j7Vqtwp3ikvGakzzg3W5ADL9GSIPa2GTAOe0hjElRTIlghFVb9O0T9DaMMRc_U0RQJrfUm8eJ_kb5s8EMiBkwMaQUoVN5P3qwYRvQur2PJU_M_ylo12rKrF9BfAi9T5KzBHnfdzZLxllvjXY_YVJtsHvce5UL4PQ |
CitedBy_id | crossref_primary_10_1016_j_nbd_2020_105157 crossref_primary_10_1002_prp2_567 crossref_primary_10_1016_j_jpain_2024_03_010 crossref_primary_10_1080_14740338_2021_1942839 crossref_primary_10_1007_s12325_021_01632_x crossref_primary_10_1111_head_13956 crossref_primary_10_3390_jcm13175156 crossref_primary_10_2174_1871527319666200618144637 crossref_primary_10_52965_001c_35506 crossref_primary_10_3389_fphys_2021_820006 crossref_primary_10_3390_pharmaceutics12121180 crossref_primary_10_1111_head_14013 crossref_primary_10_1124_mol_119_116954 crossref_primary_10_1097_WNO_0000000000000837 crossref_primary_10_1186_s10194_020_01105_6 crossref_primary_10_1016_j_clinthera_2022_01_006 crossref_primary_10_1177_0333102419840780 crossref_primary_10_4103_sjmms_sjmms_95_22 crossref_primary_10_1007_s40267_020_00801_2 crossref_primary_10_31616_asj_2023_0121 crossref_primary_10_1186_s10194_024_01717_2 crossref_primary_10_3389_fpain_2021_705276 crossref_primary_10_1186_s10194_020_01143_0 crossref_primary_10_1007_s11916_019_0768_y crossref_primary_10_1080_07853890_2021_2014556 crossref_primary_10_17925_ENR_2019_14_2_68 crossref_primary_10_2139_ssrn_3791424 crossref_primary_10_1186_s10194_019_0979_y crossref_primary_10_1111_head_13510 crossref_primary_10_52965_001c_38534 crossref_primary_10_48208_HeadacheMed_2023_16 crossref_primary_10_17116_pain20242202156 crossref_primary_10_24304_kjcp_2019_29_2_71 crossref_primary_10_52965_001c_38439 crossref_primary_10_3389_fphys_2018_01249 crossref_primary_10_1007_s40267_019_00680_2 crossref_primary_10_1111_ene_14102 crossref_primary_10_1177_0333102419877169 crossref_primary_10_1080_17512433_2020_1774361 crossref_primary_10_48208_HeadacheMed_2023_29 crossref_primary_10_1177_0333102420946725 crossref_primary_10_1007_s10787_023_01276_z crossref_primary_10_3390_ijms21176045 crossref_primary_10_1208_s12248_020_00443_2 crossref_primary_10_1097_WNF_0000000000000571 crossref_primary_10_1177_0333102420905132 crossref_primary_10_3390_neurolint16010019 crossref_primary_10_1016_j_pharep_2019_03_002 crossref_primary_10_1111_head_13414 crossref_primary_10_1111_head_13691 crossref_primary_10_1007_s40122_020_00159_3 |
Cites_doi | 10.1002/ana.410280213 10.1056/NEJMcp1605502 10.1111/j.1365-2796.1990.tb00236.x 10.1056/NEJM198203043060906 10.1016/S1474-4422(14)70209-1 10.1038/nrneurol.2010.127 10.1016/j.pharmthera.2005.04.010 10.1056/NEJMoa1709038 10.1007/s11916-015-0476-1 10.1177/0333102414547138 10.1016/S1474-4422(14)70128-0 10.1212/WNL.0000000000002801 10.1016/S1474-4422(14)70126-7 10.1212/WNL.0000000000000771 10.1517/17460441.2013.826644 10.1016/S1474-4422(14)70228-5 10.1016/j.ymeth.2005.02.001 10.1002/ana.410330109 10.1007/s11739-016-1489-4 10.1177/0333102413517775 10.1212/01.wnl.0000252808.97649.21 10.1002/ana.410230214 10.1046/j.1468-2982.2002.00310.x 10.1016/S1474-4422(15)00249-5 10.1212/WNL.0000000000004391 10.1111/bcp.12591 10.1016/j.coph.2008.12.007 10.1038/304129a0 10.1016/S1474-4422(17)30083-2 10.1097/WCO.0b013e3283466c8e 10.1124/jpet.115.227793 10.1056/NEJMoa030505 10.1016/j.clpt.2004.10.001 10.1038/bjp.2008.334 10.1016/S1474-4422(16)00019-3 10.1177/0333102416650702 10.1016/j.tips.2016.06.002 10.1016/S1474-4422(15)00245-8 10.1152/physrev.00034.2015 10.1056/NEJMoa1705848 10.1016/S1474-4422(16)00040-5 10.1212/WNL.0b013e3182a6cb72 10.1097/WCO.0000000000000438 10.1056/NEJMra010917 10.1001/jamaneurol.2017.3859 |
ContentType | Journal Article |
Copyright | 2018 The American Society for Experimental NeuroTherapeutics, Inc. The American Society for Experimental NeuroTherapeutics, Inc. 2018 Neurotherapeutics is a copyright of Springer, (2018). All Rights Reserved. |
Copyright_xml | – notice: 2018 The American Society for Experimental NeuroTherapeutics, Inc. – notice: The American Society for Experimental NeuroTherapeutics, Inc. 2018 – notice: Neurotherapeutics is a copyright of Springer, (2018). All Rights Reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM ADTOC UNPAY |
DOI | 10.1007/s13311-018-0622-7 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Psychology Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Psychology |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1878-7479 |
EndPage | 335 |
ExternalDocumentID | 10.1007/s13311-018-0622-7 PMC5935651 29616494 10_1007_s13311_018_0622_7 S1878747923015647 |
Genre | Journal Article Review |
GroupedDBID | --- --K .1- .FO 06D 0R~ 0VY 123 1B1 203 29~ 2JY 2KG 2KM 2VQ 30V 4.4 406 408 40E 53G 5VS 67N 71M 7RV 7X7 88E 8AO 8FI 8FJ 8UJ 96X AAAVM AABHQ AAEDT AAFWJ AAHNG AAIAL AAJBT AAJKR AAKDD AALRI AANXM AANZL AAQFI AARHV AARTL AATVU AAUYE AAWCG AAXUO AAYIU AAYQN AAYTO AAYWO AAYZH AAZMS ABDZT ABECU ABFSG ABFTV ABIPD ABIVO ABJOX ABKCH ABMQK ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABUWG ABWVN ABXPI ACGFS ACHSB ACKNC ACMDZ ACMLO ACOKC ACPRK ACRPL ACSTC ACVFH ADBBV ADCNI ADHIR ADJJI ADKNI ADKPE ADMUD ADNMO ADRFC ADTPH ADURQ ADVLN ADYFF ADZKW AEBTG AEGNC AEJHL AEJRE AEKER AENEX AEOHA AEPYU AESKC AETCA AEUPX AEVLU AEXYK AEZWR AFBBN AFHIU AFJKZ AFKRA AFLOW AFPKN AFPUW AFQWF AFRHN AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGII AIIXL AILAN AITGF AITUG AIXLP AJBLW AJRNO AJUYK AJZVZ AKBMS AKMHD AKRWK AKYEP ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ AMXSW AMYLF ANMIH AOCGG AOIJS APXCP ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC BENPR BGNMA BKEYQ BMSDO BPHCQ BVXVI CCPQU CS3 CSCUP DDRTE DNIVK DPUIP DU5 DWQXO DX2 EBS EIOEI EJD EN4 EO8 EO9 EP2 EP3 ESBYG EX3 F5P FDB FEDTE FERAY FFXSO FINBP FNLPD FNPLU FRRFC FSGXE FYUFA GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GROUPED_DOAJ H13 HF~ HMCUK HMJXF HRMNR HVGLF HYE HZ~ I0C IHE IKXTQ IMOTQ ITM IWAJR J-C JBSCW JZLTJ KOV LLZTM M1P M2M M41 M4Y MO0 NAPCQ NPVJJ NQ- NQJWS NU0 O9- O93 O9I O9J OK1 OZT PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PUEGO R9I RLLFE ROL RPM RPZ RSV S1Z S27 S3A S3B SBL SDG SHX SISQX SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE T13 TSG U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VFIZW W48 WK8 WOW Z5R ZMTXR ZOVNA ~A9 -56 -5G -BR -EM -~C 04C 2JN 3V. ABAKF ABULA ACZOJ ADINQ AEFQL AFCTW ALIPV EIHBH GQ6 RIG SV3 Z7U Z83 Z87 AAYXX CITATION EBLON ~HD CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM ADTOC UNPAY |
ID | FETCH-LOGICAL-c546t-9f52a16318bc0297e99373ce2c1454d572bec794f3e6d582d559096a3cf6325a3 |
IEDL.DBID | 7X7 |
ISSN | 1878-7479 1933-7213 |
IngestDate | Tue Aug 26 13:26:51 EDT 2025 Tue Sep 30 16:59:59 EDT 2025 Sat Sep 27 23:51:00 EDT 2025 Wed Aug 13 07:15:00 EDT 2025 Thu Apr 03 07:04:02 EDT 2025 Wed Oct 01 02:56:10 EDT 2025 Thu Apr 24 22:57:42 EDT 2025 Fri Feb 21 02:34:38 EST 2025 Tue Aug 26 20:09:50 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Efficacy Tolerability Safety Migraine |
Language | English |
License | http://www.elsevier.com/open-access/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c546t-9f52a16318bc0297e99373ce2c1454d572bec794f3e6d582d559096a3cf6325a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0002-8527-0725 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/content/pdf/10.1007/s13311-018-0622-7.pdf |
PMID | 29616494 |
PQID | 2021172391 |
PQPubID | 1476362 |
PageCount | 12 |
ParticipantIDs | unpaywall_primary_10_1007_s13311_018_0622_7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5935651 proquest_miscellaneous_2021731341 proquest_journals_2021172391 pubmed_primary_29616494 crossref_citationtrail_10_1007_s13311_018_0622_7 crossref_primary_10_1007_s13311_018_0622_7 springer_journals_10_1007_s13311_018_0622_7 elsevier_clinicalkey_doi_10_1007_s13311_018_0622_7 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-04-01 |
PublicationDateYYYYMMDD | 2018-04-01 |
PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: United States – name: New York |
PublicationSubtitle | The Journal of the American Society for Experimental NeuroTherapeutics |
PublicationTitle | Neurotherapeutics |
PublicationTitleAbbrev | Neurotherapeutics |
PublicationTitleAlternate | Neurotherapeutics |
PublicationYear | 2018 |
Publisher | Elsevier Inc Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Elsevier Inc – name: Springer International Publishing – name: Springer Nature B.V |
References | Shi, Lehto, Zhu (bib52) 2016; 356 Alder Biopharmaceuticals, Inc. Evaluation of ALD403 (eptinezumab) in the prevention of chronic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02974153. Accessed 29 August 2017. Ho, Ho, Ge (bib23) 2014; 83 Goadsby, Edvinsson (bib16) 1993; 33 Rosenfeld, Mermod, Amara (bib8) 1983; 304 Bigal, Edvinsson, Rapoport (bib47) 2015; 14 Goadsby, Edvinsson, Ekman (bib9) 1988; 23 Eli Lilly and Company. A study of LY2951742 in healthy Japanese and Caucasian participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02104765. Accessed 29 August 2017. Petersen, Lassen, Birk, Lesko, Olesen (bib22) 2005; 77 Giamberardino, Affaitati, Curto (bib3) 2016; 11 Miller, Maloney, Warnke, Levy (bib26) 1982; 306 Alder Biopharmaceuticals, Inc. A multicenter assessment of ALD403 in frequent episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02559895. Accessed 29 August 2017. Eli Lilly and Company. A study of LY2951742 in healthy volunteers. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01337596. Accessed 29 August 2017. De Hoon, Van Hecken, Vandermeulen, Yan, Vu, Vargas (bib53) 2017 Dodick, Goadsby, Silberstein (bib33) 2017; 88 Cernuda-Morollon, Larrosa, Ramon (bib17) 2013; 81 Dodick, Goadsby, Spierings (bib39) 2014; 13 Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of subcutaneous administration of TEV-48125 for the preventive treatment of migraine. Available at: https://clinicaltrials.gov/ct2/show/NCT02638103. Accessed 29 August 2017. Edvinsson, Goadsby (bib13) 1990; 228 Bigal, Escandon, Bronson (bib29) 2014; 34 Skljarevski V, Oakes TM, Zhang Q, et al., Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2017. doi: https://doi.org/10.1001/jamaneurol.2017.385. Bigal, Dodick, Rapoport (bib46) 2015; 14 Bigal, Dodick, Krymchantowski (bib48) 2016; 87 Benemei, Nicoletti, Capone, Geppetti (bib21) 2009; 9 Labruijere, Ibrahimi, Chan, MaassenVanDenBrink (bib24) 2013; 8 Hepp, Dodick, Varon (bib2) 2015; 35 Eli Lilly and Company. A study of LY2951742 in healthy participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02576951. Accessed 29 August 2017. Ho, Edvinsson, Goadsby (bib10) 2010; 6 Amgen. Study to evaluate the effect on blood pressure of AMG 334 given concomitantly with subcutaneous sumatriptan. 2017. Available at: https://clinicaltrials.gov/ct2/show/NTC02741310. Accessed 29 August 2017. Goadsby, Reuter, Hallström (bib59) 2017; 377 Olesen, Diener, Husstedt (bib12) 2004; 350 Goadbsy, Lipton, Ferrari (bib7) 2002; 346 Pellesi, Guerzoni, Pini (bib30) 2017; 00 Bigal, Walter, Rapoport (bib28) 2015; 79 Silberstein, Dodick, Bigal (bib50) 2017; 377 Ramadan, Buchanan (bib4) 2006; 112 Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02629861. Accessed 29 August 2017. Sun, Dodick, Silberstein (bib55) 2016; 15 Goadsby, Holland, Martins-Oliveira (bib6) 2017; 97 Eli Lilly and Company. A safety study of LY2951742 in participants with migraine, with or without aura. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614287. Accessed 29 August 2017. Baker B, Hodsman P, Smith J. PK & PD supporting a single dose, placebo-controlled randomized ascending dose study of ALD403, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered IV or SC. Available at: http://www.alderbio.com/wp-content/uploads/2016/08/ALD403-EHMTIC-Poster-Baker-29-August-2016-Portrait-WO-QR-Code.pdf. Accessed 29 August 2017. Ramos, Pascual (bib14) 2016; 15 Reuter (bib25) 2014; 13 Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02174861. Accessed 29 August 2017. Dodick, Ashina, Kudrow (bib58) 2017; e1 Dodick, Goadsby, Silberstein (bib31) 2014; 13 MaassenVanDenBrink, Meijer, Villalón, Ferrari (bib11) 2016; 37 Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-1 study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614183. Accessed 29 August 2017. Diener (bib63) 2014; 13 Charles (bib62) 2017; 377 Lipton, Bigal, Diamond (bib1) 2007; 68 Eli Lilly and Company. Evaluation of LY2951742 in the prevention of chronic migraine (REGAIN). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614261. Accessed 29 August 2017. Ashina, Dodick, Goadsby (bib56) 2017; 89 Tepper, Ashina, Reuter (bib57) 2017; 16 Zeller, Poulsen, Sutton (bib64) 2008; 155 Gracia-Naya, Santos-Lasaosa, Rios-Gomez (bib5) 2011; 53 Walter, Bigal (bib45) 2015; 19 Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-2 Study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614196. Accessed 29 August 2017. Lassen, Haderslev, Jacobsen (bib18) 2002; 22 Noseda, Burstein (bib19) 2011; 24 Kopruszinski, Xie, Eyde (bib20) 2016; 37 Goadsby, Edvinsson, Ekman (bib15) 1990; 28 Wu, Dall'Acqua (bib27) 2005; 36 Mitsikostas, Reuter (bib61) 2017; 30 Labruijere, Ibrahimi, Chan, MaassenVanDenBrink (CR24) 2013; 8 Dodick, Goadsby, Silberstein (CR31) 2014; 13 Bigal, Escandon, Bronson (CR29) 2014; 34 Tepper, Ashina, Reuter (CR57) 2017; 16 Silberstein, Dodick, Bigal (CR50) 2017; 377 CR38 Hepp, Dodick, Varon (CR2) 2015; 35 CR37 CR36 CR35 CR34 Dodick, Goadsby, Silberstein (CR33) 2017; 88 CR32 Walter, Bigal (CR45) 2015; 19 Bigal, Walter, Rapoport (CR28) 2015; 79 Benemei, Nicoletti, Capone, Geppetti (CR21) 2009; 9 Shi, Lehto, Zhu (CR52) 2016; 356 Goadsby, Edvinsson, Ekman (CR9) 1988; 23 Olesen, Diener, Husstedt (CR12) 2004; 350 Goadsby, Reuter, Hallström (CR59) 2017; 377 Wu, Dall’Acqua (CR27) 2005; 36 Lassen, Haderslev, Jacobsen (CR18) 2002; 22 Bigal, Dodick, Krymchantowski (CR48) 2016; 87 Cernuda-Morollon, Larrosa, Ramon (CR17) 2013; 81 Petersen, Lassen, Birk, Lesko, Olesen (CR22) 2005; 77 CR49 Gracia-Naya, Santos-Lasaosa, Rios-Gomez (CR5) 2011; 53 Kopruszinski, Xie, Eyde (CR20) 2016; 37 CR44 CR43 Ho, Edvinsson, Goadsby (CR10) 2010; 6 CR42 CR41 CR40 Pellesi, Guerzoni, Pini (CR30) 2017; 00 Miller, Maloney, Warnke, Levy (CR26) 1982; 306 Ramos, Pascual (CR14) 2016; 15 Ho, Ho, Ge (CR23) 2014; 83 Ramadan, Buchanan (CR4) 2006; 112 Mitsikostas, Reuter (CR61) 2017; 30 Zeller, Poulsen, Sutton (CR64) 2008; 155 Giamberardino, Affaitati, Curto (CR3) 2016; 11 Edvinsson, Goadsby (CR13) 1990; 228 Goadsby, Edvinsson (CR16) 1993; 33 Noseda, Burstein (CR19) 2011; 24 Charles (CR62) 2017; 377 CR54 CR53 MaassenVanDenBrink, Meijer, Villalón, Ferrari (CR11) 2016; 37 Reuter (CR25) 2014; 13 CR51 Sun, Dodick, Silberstein (CR55) 2016; 15 Rosenfeld, Mermod, Amara (CR8) 1983; 304 Dodick, Goadsby, Spierings (CR39) 2014; 13 Dodick, Ashina, Kudrow (CR58) 2017; e1 Diener (CR63) 2014; 13 Goadbsy, Lipton, Ferrari (CR7) 2002; 346 Goadsby, Edvinsson, Ekman (CR15) 1990; 28 Bigal, Edvinsson, Rapoport (CR47) 2015; 14 Bigal, Dodick, Rapoport (CR46) 2015; 14 Lipton, Bigal, Diamond (CR1) 2007; 68 CR60 Goadsby, Holland, Martins-Oliveira (CR6) 2017; 97 Ashina, Dodick, Goadsby (CR56) 2017; 89 Walter (10.1007/s13311-018-0622-7_bib45) 2015; 19 Rosenfeld (10.1007/s13311-018-0622-7_bib8) 1983; 304 Ho (10.1007/s13311-018-0622-7_bib23) 2014; 83 Mitsikostas (10.1007/s13311-018-0622-7_bib61) 2017; 30 Cernuda-Morollon (10.1007/s13311-018-0622-7_bib17) 2013; 81 Petersen (10.1007/s13311-018-0622-7_bib22) 2005; 77 10.1007/s13311-018-0622-7_bib36 10.1007/s13311-018-0622-7_bib37 10.1007/s13311-018-0622-7_bib34 10.1007/s13311-018-0622-7_bib35 Hepp (10.1007/s13311-018-0622-7_bib2) 2015; 35 Ashina (10.1007/s13311-018-0622-7_bib56) 2017; 89 Benemei (10.1007/s13311-018-0622-7_bib21) 2009; 9 10.1007/s13311-018-0622-7_bib38 Goadsby (10.1007/s13311-018-0622-7_bib16) 1993; 33 10.1007/s13311-018-0622-7_bib32 Goadsby (10.1007/s13311-018-0622-7_bib59) 2017; 377 Dodick (10.1007/s13311-018-0622-7_bib31) 2014; 13 Lipton (10.1007/s13311-018-0622-7_bib1) 2007; 68 Ramos (10.1007/s13311-018-0622-7_bib14) 2016; 15 Ramadan (10.1007/s13311-018-0622-7_bib4) 2006; 112 Diener (10.1007/s13311-018-0622-7_bib63) 2014; 13 Bigal (10.1007/s13311-018-0622-7_bib47) 2015; 14 Goadbsy (10.1007/s13311-018-0622-7_bib7) 2002; 346 Labruijere (10.1007/s13311-018-0622-7_bib24) 2013; 8 Kopruszinski (10.1007/s13311-018-0622-7_bib20) 2016; 37 Ho (10.1007/s13311-018-0622-7_bib10) 2010; 6 MaassenVanDenBrink (10.1007/s13311-018-0622-7_bib11) 2016; 37 10.1007/s13311-018-0622-7_bib49 10.1007/s13311-018-0622-7_bib40 Wu (10.1007/s13311-018-0622-7_bib27) 2005; 36 10.1007/s13311-018-0622-7_bib43 Shi (10.1007/s13311-018-0622-7_bib52) 2016; 356 10.1007/s13311-018-0622-7_bib44 10.1007/s13311-018-0622-7_bib41 Bigal (10.1007/s13311-018-0622-7_bib48) 2016; 87 10.1007/s13311-018-0622-7_bib42 Tepper (10.1007/s13311-018-0622-7_bib57) 2017; 16 Dodick (10.1007/s13311-018-0622-7_bib39) 2014; 13 Lassen (10.1007/s13311-018-0622-7_bib18) 2002; 22 Pellesi (10.1007/s13311-018-0622-7_bib30) 2017; 00 Bigal (10.1007/s13311-018-0622-7_bib46) 2015; 14 Gracia-Naya (10.1007/s13311-018-0622-7_bib5) 2011; 53 Goadsby (10.1007/s13311-018-0622-7_bib15) 1990; 28 Charles (10.1007/s13311-018-0622-7_bib62) 2017; 377 10.1007/s13311-018-0622-7_bib51 Zeller (10.1007/s13311-018-0622-7_bib64) 2008; 155 10.1007/s13311-018-0622-7_bib54 Dodick (10.1007/s13311-018-0622-7_bib33) 2017; 88 Dodick (10.1007/s13311-018-0622-7_bib58) 2017; e1 De Hoon (10.1007/s13311-018-0622-7_bib53) 2017 Goadsby (10.1007/s13311-018-0622-7_bib6) 2017; 97 Bigal (10.1007/s13311-018-0622-7_bib28) 2015; 79 Miller (10.1007/s13311-018-0622-7_bib26) 1982; 306 Sun (10.1007/s13311-018-0622-7_bib55) 2016; 15 Olesen (10.1007/s13311-018-0622-7_bib12) 2004; 350 Bigal (10.1007/s13311-018-0622-7_bib29) 2014; 34 Silberstein (10.1007/s13311-018-0622-7_bib50) 2017; 377 10.1007/s13311-018-0622-7_bib60 Giamberardino (10.1007/s13311-018-0622-7_bib3) 2016; 11 Goadsby (10.1007/s13311-018-0622-7_bib9) 1988; 23 Noseda (10.1007/s13311-018-0622-7_bib19) 2011; 24 Reuter (10.1007/s13311-018-0622-7_bib25) 2014; 13 Edvinsson (10.1007/s13311-018-0622-7_bib13) 1990; 228 |
References_xml | – volume: 89 start-page: 1237 year: 2017 end-page: 1243 ident: bib56 article-title: Erenumab (AMG334) in episodic migraine. Interim analysis of an ongoing open-label study publication-title: Neurology. – volume: 37 start-page: 779 year: 2016 end-page: 788 ident: bib11 article-title: Wiping out CGRP: potential cardiovascular risks publication-title: Trends Pharmacol Sci. – reference: Eli Lilly and Company. Evaluation of LY2951742 in the prevention of chronic migraine (REGAIN). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614261. Accessed 29 August 2017. – volume: 15 start-page: 382 year: 2016 end-page: 390 ident: bib55 article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Neurol. – volume: 6 start-page: 573 year: 2010 end-page: 582 ident: bib10 article-title: CGRP and its receptors provide new insights into migraine pathophysiology publication-title: Nat Rev Neurol. – volume: 83 start-page: 958 year: 2014 end-page: 966 ident: bib23 article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention publication-title: Neurology. – volume: 00 start-page: 1 year: 2017 end-page: 14 ident: bib30 article-title: Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date publication-title: Clin Pharmacol Drug Dev. – reference: Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of subcutaneous administration of TEV-48125 for the preventive treatment of migraine. Available at: https://clinicaltrials.gov/ct2/show/NCT02638103. Accessed 29 August 2017. – reference: Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-1 study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614183. Accessed 29 August 2017. – reference: Eli Lilly and Company. A study of LY2951742 in healthy participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02576951. Accessed 29 August 2017. – volume: 37 start-page: 560 year: 2016 end-page: 570 ident: bib20 article-title: Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents publication-title: Cephalalgia. – volume: 16 start-page: 425 year: 2017 end-page: 434 ident: bib57 article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial publication-title: Lancet Neurol – volume: 30 start-page: 272 year: 2017 end-page: 280 ident: bib61 article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies publication-title: Curr Opin Neurol. – reference: Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02629861. Accessed 29 August 2017. – volume: 13 start-page: 1065 year: 2014 end-page: 1067 ident: bib63 article-title: CGRP as a new target in prevention and treatment of migraine publication-title: Lancet Neurol. – volume: 14 start-page: 1091 year: 2015 end-page: 1100 ident: bib47 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol. – year: 2017 ident: bib53 article-title: Phase 1, randomized, double-blind, placebo-controlled, single-dose and multiple-dose studies of erenumab in healthy subjects and patients with migraine. publication-title: Clin Pharmacol Ther. – volume: 97 start-page: 553 year: 2017 end-page: 622 ident: bib6 article-title: Pathophysiology of migraine: a disorder of sensory processing publication-title: Physiol Rev. – volume: 306 start-page: 517 year: 1982 end-page: 522 ident: bib26 article-title: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody publication-title: N Engl J Med. – volume: 13 start-page: 885 year: 2014 end-page: 892 ident: bib39 article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study publication-title: Lancet Neurol. – volume: 87 start-page: 41 year: 2016 end-page: 48 ident: bib48 article-title: TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points publication-title: Neurology. – volume: 155 start-page: 1093 year: 2008 end-page: 1103 ident: bib64 article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat publication-title: Br J Pharmacol. – volume: 36 start-page: 1 year: 2005 end-page: 2 ident: bib27 article-title: Humanized antibodies and their applications publication-title: Methods. – volume: 77 start-page: 202 year: 2005 end-page: 213 ident: bib22 article-title: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation publication-title: Clin Pharmacol Ther. – volume: 11 start-page: 1045 year: 2016 end-page: 1057 ident: bib3 article-title: Anti-CGRP monoclonal antibodies in migraine: current perspectives publication-title: Intern Emerg Med. – volume: 53 start-page: 201 year: 2011 end-page: 208 ident: bib5 article-title: Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine publication-title: Rev Neurol. – reference: Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-2 Study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614196. Accessed 29 August 2017. – reference: Baker B, Hodsman P, Smith J. PK & PD supporting a single dose, placebo-controlled randomized ascending dose study of ALD403, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered IV or SC. Available at: http://www.alderbio.com/wp-content/uploads/2016/08/ALD403-EHMTIC-Poster-Baker-29-August-2016-Portrait-WO-QR-Code.pdf. Accessed 29 August 2017. – volume: e1 start-page: 88 year: 2017 ident: bib58 article-title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the ARISE trial publication-title: J Neurol Neurosurg Psychiatry. – volume: 33 start-page: 48 year: 1993 end-page: 56 ident: bib16 article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats publication-title: Ann Neurol. – reference: Alder Biopharmaceuticals, Inc. Evaluation of ALD403 (eptinezumab) in the prevention of chronic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02974153. Accessed 29 August 2017. – volume: 377 start-page: 553 year: 2017 end-page: 561 ident: bib62 article-title: Migraine publication-title: N Engl J Med. – volume: 350 start-page: 1104 year: 2004 end-page: 1110 ident: bib12 article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine publication-title: N Engl J Med. – volume: 68 start-page: 343 year: 2007 end-page: 349 ident: bib1 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology – volume: 19 start-page: 6 year: 2015 ident: bib45 article-title: TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine publication-title: Curr Pain Headache Rep. – volume: 13 start-page: 1100 year: 2014 end-page: 1107 ident: bib31 article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial publication-title: Lancet Neurol. – volume: 79 start-page: 886 year: 2015 end-page: 895 ident: bib28 article-title: Therapeutic antibodies against CGRP or its receptor publication-title: Br J Clin Pharmacol. – volume: 9 start-page: 9 year: 2009 end-page: 14 ident: bib21 article-title: CGRP receptors in the control of pain and inflammation publication-title: Curr Opin Pharmacol. – volume: 88 year: 2017 ident: bib33 article-title: Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine publication-title: Neurology – volume: 13 start-page: 857 year: 2014 end-page: 859 ident: bib25 article-title: Anti-CGRP antibodies: a new approach to migraine prevention publication-title: Lancet Neurol. – volume: 304 start-page: 129 year: 1983 end-page: 135 ident: bib8 article-title: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing publication-title: Nature. – volume: 23 start-page: 193 year: 1988 end-page: 196 ident: bib9 article-title: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system publication-title: Ann Neurol. – reference: Alder Biopharmaceuticals, Inc. A multicenter assessment of ALD403 in frequent episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02559895. Accessed 29 August 2017. – volume: 34 start-page: 483 year: 2014 end-page: 492 ident: bib29 article-title: Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program publication-title: Cephalalgia. – reference: Eli Lilly and Company. A study of LY2951742 in healthy Japanese and Caucasian participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02104765. Accessed 29 August 2017. – volume: 24 start-page: 197 year: 2011 end-page: 202 ident: bib19 article-title: Advances in understanding the mechanisms of migraine-type photophobia publication-title: Curr Opin Neurol. – reference: Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02174861. Accessed 29 August 2017. – volume: 15 start-page: 347 year: 2016 end-page: 349 ident: bib14 article-title: AMG 334 CGRP antibody for migraine: time to celebrate? publication-title: Lancet Neurol. – reference: Eli Lilly and Company. A study of LY2951742 in healthy volunteers. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01337596. Accessed 29 August 2017. – reference: Skljarevski V, Oakes TM, Zhang Q, et al., Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2017. doi: https://doi.org/10.1001/jamaneurol.2017.385. – volume: 8 start-page: 1309 year: 2013 end-page: 1323 ident: bib24 article-title: Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies publication-title: Expert Opin Drug Discov. – volume: 28 start-page: 183 year: 1990 end-page: 187 ident: bib15 article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache publication-title: Ann Neurol. – volume: 346 start-page: 257 year: 2002 end-page: 270 ident: bib7 article-title: Migraine—current understanding and treatment publication-title: N Engl J Med. – volume: 81 start-page: 1191 year: 2013 end-page: 1196 ident: bib17 article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine publication-title: Neurology. – volume: 228 start-page: 299 year: 1990 end-page: 304 ident: bib13 article-title: Extracerebral manifestations in migraine. A peptidergic involvement? publication-title: J Intern Med. – volume: 356 start-page: 223 year: 2016 end-page: 231 ident: bib52 article-title: Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor publication-title: J Pharmacol Exp Ther. – reference: Amgen. Study to evaluate the effect on blood pressure of AMG 334 given concomitantly with subcutaneous sumatriptan. 2017. Available at: https://clinicaltrials.gov/ct2/show/NTC02741310. Accessed 29 August 2017. – volume: 377 start-page: 2123 year: 2017 end-page: 2132 ident: bib59 article-title: A controlled trial of erenumab for episodic migraine publication-title: N Engl J Med. – volume: 35 start-page: 478 year: 2015 end-page: 488 ident: bib2 article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine publication-title: Cephalalgia. – volume: 377 start-page: 2113 year: 2017 end-page: 2122 ident: bib50 article-title: Fremanezumab for the preventive treatment of chronic migraine publication-title: N Engl J Med. – volume: 14 start-page: 1081 year: 2015 end-page: 1090 ident: bib46 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol. – volume: 22 start-page: 54 year: 2002 end-page: 61 ident: bib18 article-title: CGRP may play a causative role in migraine publication-title: Cephalalgia. – volume: 112 start-page: 199 year: 2006 end-page: 212 ident: bib4 article-title: New and future migraine therapy publication-title: Pharmacol Ther. – reference: Eli Lilly and Company. A safety study of LY2951742 in participants with migraine, with or without aura. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614287. Accessed 29 August 2017. – volume: 28 start-page: 183 issue: 2 year: 1990 end-page: 7 ident: CR15 article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache publication-title: Ann Neurol. doi: 10.1002/ana.410280213 – ident: CR49 – ident: CR51 – volume: e1 start-page: 88 year: 2017 ident: CR58 article-title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the ARISE trial publication-title: J Neurol Neurosurg Psychiatry. – volume: 377 start-page: 553 year: 2017 end-page: 561 ident: CR62 article-title: Migraine publication-title: N Engl J Med. doi: 10.1056/NEJMcp1605502 – volume: 228 start-page: 299 year: 1990 end-page: 304 ident: CR13 article-title: Extracerebral manifestations in migraine. A peptidergic involvement? publication-title: J Intern Med. doi: 10.1111/j.1365-2796.1990.tb00236.x – volume: 306 start-page: 517 issue: 9 year: 1982 end-page: 22 ident: CR26 article-title: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody publication-title: N Engl J Med. doi: 10.1056/NEJM198203043060906 – volume: 13 start-page: 1100 issue: 11 year: 2014 end-page: 1107 ident: CR31 article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70209-1 – volume: 6 start-page: 573 year: 2010 end-page: 82 ident: CR10 article-title: CGRP and its receptors provide new insights into migraine pathophysiology publication-title: Nat Rev Neurol. doi: 10.1038/nrneurol.2010.127 – ident: CR35 – ident: CR54 – volume: 53 start-page: 201 issue: 4 year: 2011 end-page: 8 ident: CR5 article-title: Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine publication-title: Rev Neurol. – volume: 112 start-page: 199 year: 2006 end-page: 212 ident: CR4 article-title: New and future migraine therapy publication-title: Pharmacol Ther. doi: 10.1016/j.pharmthera.2005.04.010 – volume: 377 start-page: 2113 year: 2017 end-page: 2122 ident: CR50 article-title: Fremanezumab for the preventive treatment of chronic migraine publication-title: N Engl J Med. doi: 10.1056/NEJMoa1709038 – ident: CR42 – volume: 19 start-page: 6 year: 2015 ident: CR45 article-title: TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine publication-title: Curr Pain Headache Rep. doi: 10.1007/s11916-015-0476-1 – volume: 35 start-page: 478 year: 2015 end-page: 88 ident: CR2 article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine publication-title: Cephalalgia. doi: 10.1177/0333102414547138 – volume: 13 start-page: 885 issue: 9 year: 2014 end-page: 892 ident: CR39 article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70128-0 – volume: 87 start-page: 41 year: 2016 end-page: 48 ident: CR48 article-title: TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points publication-title: Neurology. doi: 10.1212/WNL.0000000000002801 – volume: 13 start-page: 857 year: 2014 end-page: 859 ident: CR25 article-title: Anti-CGRP antibodies: a new approach to migraine prevention publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70126-7 – volume: 83 start-page: 958 issue: 11 year: 2014 end-page: 66 ident: CR23 article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention publication-title: Neurology. doi: 10.1212/WNL.0000000000000771 – volume: 8 start-page: 1309 year: 2013 end-page: 23 ident: CR24 article-title: Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies publication-title: Expert Opin Drug Discov. doi: 10.1517/17460441.2013.826644 – volume: 00 start-page: 1 year: 2017 end-page: 14 ident: CR30 article-title: Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date publication-title: Clin Pharmacol Drug Dev. – volume: 13 start-page: 1065 issue: 11 year: 2014 end-page: 7 ident: CR63 article-title: CGRP as a new target in prevention and treatment of migraine publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70228-5 – volume: 36 start-page: 1 issue: 1 year: 2005 end-page: 2 ident: CR27 article-title: Humanized antibodies and their applications publication-title: Methods. doi: 10.1016/j.ymeth.2005.02.001 – volume: 33 start-page: 48 issue: 1 year: 1993 end-page: 56 ident: CR16 article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats publication-title: Ann Neurol. doi: 10.1002/ana.410330109 – volume: 11 start-page: 1045 issue: 8 year: 2016 end-page: 1057 ident: CR3 article-title: Anti-CGRP monoclonal antibodies in migraine: current perspectives publication-title: Intern Emerg Med. doi: 10.1007/s11739-016-1489-4 – volume: 34 start-page: 483 issue: 7 year: 2014 end-page: 492 ident: CR29 article-title: Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program publication-title: Cephalalgia. doi: 10.1177/0333102413517775 – ident: CR32 – ident: CR60 – ident: CR36 – volume: 68 start-page: 343 year: 2007 end-page: 9 ident: CR1 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology doi: 10.1212/01.wnl.0000252808.97649.21 – volume: 23 start-page: 193 year: 1988 end-page: 6 ident: CR9 article-title: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system publication-title: Ann Neurol. doi: 10.1002/ana.410230214 – volume: 22 start-page: 54 year: 2002 end-page: 61 ident: CR18 article-title: CGRP may play a causative role in migraine publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.2002.00310.x – volume: 14 start-page: 1081 issue: 11 year: 2015 end-page: 1090 ident: CR46 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(15)00249-5 – ident: CR43 – volume: 89 start-page: 1237 year: 2017 end-page: 43 ident: CR56 article-title: Erenumab (AMG334) in episodic migraine. Interim analysis of an ongoing open-label study publication-title: Neurology. doi: 10.1212/WNL.0000000000004391 – volume: 79 start-page: 886 issue: 6 year: 2015 end-page: 895 ident: CR28 article-title: Therapeutic antibodies against CGRP or its receptor publication-title: Br J Clin Pharmacol. doi: 10.1111/bcp.12591 – volume: 88 issue: 16 Supplement year: 2017 ident: CR33 article-title: Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine publication-title: Neurology – volume: 9 start-page: 9 year: 2009 end-page: 14 ident: CR21 article-title: CGRP receptors in the control of pain and inflammation publication-title: Curr Opin Pharmacol. doi: 10.1016/j.coph.2008.12.007 – ident: CR37 – ident: CR53 – volume: 304 start-page: 129 issue: 5922 year: 1983 end-page: 35 ident: CR8 article-title: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing publication-title: Nature. doi: 10.1038/304129a0 – volume: 16 start-page: 425 year: 2017 end-page: 34 ident: CR57 article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30083-2 – volume: 24 start-page: 197 issue: 3 year: 2011 end-page: 202 ident: CR19 article-title: Advances in understanding the mechanisms of migraine-type photophobia publication-title: Curr Opin Neurol. doi: 10.1097/WCO.0b013e3283466c8e – volume: 356 start-page: 223 year: 2016 end-page: 231 ident: CR52 article-title: Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor publication-title: J Pharmacol Exp Ther. doi: 10.1124/jpet.115.227793 – volume: 350 start-page: 1104 year: 2004 end-page: 10 ident: CR12 article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine publication-title: N Engl J Med. doi: 10.1056/NEJMoa030505 – ident: CR40 – volume: 77 start-page: 202 issue: 3 year: 2005 end-page: 213 ident: CR22 article-title: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation publication-title: Clin Pharmacol Ther. doi: 10.1016/j.clpt.2004.10.001 – volume: 155 start-page: 1093 issue: 7 year: 2008 end-page: 103 ident: CR64 article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat publication-title: Br J Pharmacol. doi: 10.1038/bjp.2008.334 – volume: 15 start-page: 382 issue: 4 year: 2016 end-page: 390 ident: CR55 article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(16)00019-3 – volume: 37 start-page: 560 issue: 6 year: 2016 end-page: 570 ident: CR20 article-title: Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents publication-title: Cephalalgia. doi: 10.1177/0333102416650702 – volume: 37 start-page: 779 year: 2016 end-page: 788 ident: CR11 article-title: Wiping out CGRP: potential cardiovascular risks publication-title: Trends Pharmacol Sci. doi: 10.1016/j.tips.2016.06.002 – ident: CR44 – volume: 14 start-page: 1091 issue: 11 year: 2015 end-page: 1100 ident: CR47 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(15)00245-8 – ident: CR38 – volume: 97 start-page: 553 year: 2017 end-page: 622 ident: CR6 article-title: Pathophysiology of migraine: a disorder of sensory processing publication-title: Physiol Rev. doi: 10.1152/physrev.00034.2015 – volume: 377 start-page: 2123 year: 2017 end-page: 2132 ident: CR59 article-title: A controlled trial of erenumab for episodic migraine publication-title: N Engl J Med. doi: 10.1056/NEJMoa1705848 – volume: 15 start-page: 347 issue: 4 year: 2016 end-page: 349 ident: CR14 article-title: AMG 334 CGRP antibody for migraine: time to celebrate? publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(16)00040-5 – ident: CR34 – volume: 81 start-page: 1191 year: 2013 end-page: 1196 ident: CR17 article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine publication-title: Neurology. doi: 10.1212/WNL.0b013e3182a6cb72 – volume: 30 start-page: 272 year: 2017 end-page: 80 ident: CR61 article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies publication-title: Curr Opin Neurol. doi: 10.1097/WCO.0000000000000438 – ident: CR41 – volume: 346 start-page: 257 issue: 4 year: 2002 end-page: 270 ident: CR7 article-title: Migraine—current understanding and treatment publication-title: N Engl J Med. doi: 10.1056/NEJMra010917 – volume: 53 start-page: 201 issue: 4 year: 2011 ident: 10.1007/s13311-018-0622-7_bib5 article-title: Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine publication-title: Rev Neurol. – volume: 9 start-page: 9 year: 2009 ident: 10.1007/s13311-018-0622-7_bib21 article-title: CGRP receptors in the control of pain and inflammation publication-title: Curr Opin Pharmacol. doi: 10.1016/j.coph.2008.12.007 – ident: 10.1007/s13311-018-0622-7_bib49 – volume: 13 start-page: 1065 issue: 11 year: 2014 ident: 10.1007/s13311-018-0622-7_bib63 article-title: CGRP as a new target in prevention and treatment of migraine publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70228-5 – ident: 10.1007/s13311-018-0622-7_bib51 – volume: 33 start-page: 48 issue: 1 year: 1993 ident: 10.1007/s13311-018-0622-7_bib16 article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats publication-title: Ann Neurol. doi: 10.1002/ana.410330109 – volume: 00 start-page: 1 year: 2017 ident: 10.1007/s13311-018-0622-7_bib30 article-title: Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date publication-title: Clin Pharmacol Drug Dev. – volume: 79 start-page: 886 issue: 6 year: 2015 ident: 10.1007/s13311-018-0622-7_bib28 article-title: Therapeutic antibodies against CGRP or its receptor publication-title: Br J Clin Pharmacol. doi: 10.1111/bcp.12591 – volume: 377 start-page: 2123 year: 2017 ident: 10.1007/s13311-018-0622-7_bib59 article-title: A controlled trial of erenumab for episodic migraine publication-title: N Engl J Med. doi: 10.1056/NEJMoa1705848 – volume: 112 start-page: 199 year: 2006 ident: 10.1007/s13311-018-0622-7_bib4 article-title: New and future migraine therapy publication-title: Pharmacol Ther. doi: 10.1016/j.pharmthera.2005.04.010 – volume: 304 start-page: 129 issue: 5922 year: 1983 ident: 10.1007/s13311-018-0622-7_bib8 article-title: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing publication-title: Nature. doi: 10.1038/304129a0 – volume: 88 issue: 16 Supplement year: 2017 ident: 10.1007/s13311-018-0622-7_bib33 article-title: Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine publication-title: Neurology – volume: 30 start-page: 272 year: 2017 ident: 10.1007/s13311-018-0622-7_bib61 article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies publication-title: Curr Opin Neurol. doi: 10.1097/WCO.0000000000000438 – ident: 10.1007/s13311-018-0622-7_bib35 – ident: 10.1007/s13311-018-0622-7_bib42 – ident: 10.1007/s13311-018-0622-7_bib54 – volume: 14 start-page: 1081 issue: 11 year: 2015 ident: 10.1007/s13311-018-0622-7_bib46 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(15)00249-5 – volume: 97 start-page: 553 year: 2017 ident: 10.1007/s13311-018-0622-7_bib6 article-title: Pathophysiology of migraine: a disorder of sensory processing publication-title: Physiol Rev. doi: 10.1152/physrev.00034.2015 – volume: 356 start-page: 223 year: 2016 ident: 10.1007/s13311-018-0622-7_bib52 article-title: Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor publication-title: J Pharmacol Exp Ther. doi: 10.1124/jpet.115.227793 – volume: 77 start-page: 202 issue: 3 year: 2005 ident: 10.1007/s13311-018-0622-7_bib22 article-title: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation publication-title: Clin Pharmacol Ther. doi: 10.1016/j.clpt.2004.10.001 – volume: 89 start-page: 1237 year: 2017 ident: 10.1007/s13311-018-0622-7_bib56 article-title: Erenumab (AMG334) in episodic migraine. Interim analysis of an ongoing open-label study publication-title: Neurology. doi: 10.1212/WNL.0000000000004391 – volume: 14 start-page: 1091 issue: 11 year: 2015 ident: 10.1007/s13311-018-0622-7_bib47 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(15)00245-8 – volume: 81 start-page: 1191 year: 2013 ident: 10.1007/s13311-018-0622-7_bib17 article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine publication-title: Neurology. doi: 10.1212/WNL.0b013e3182a6cb72 – volume: 19 start-page: 6 year: 2015 ident: 10.1007/s13311-018-0622-7_bib45 article-title: TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine publication-title: Curr Pain Headache Rep. doi: 10.1007/s11916-015-0476-1 – ident: 10.1007/s13311-018-0622-7_bib32 – volume: 228 start-page: 299 year: 1990 ident: 10.1007/s13311-018-0622-7_bib13 article-title: Extracerebral manifestations in migraine. A peptidergic involvement? publication-title: J Intern Med. doi: 10.1111/j.1365-2796.1990.tb00236.x – volume: 24 start-page: 197 issue: 3 year: 2011 ident: 10.1007/s13311-018-0622-7_bib19 article-title: Advances in understanding the mechanisms of migraine-type photophobia publication-title: Curr Opin Neurol. doi: 10.1097/WCO.0b013e3283466c8e – ident: 10.1007/s13311-018-0622-7_bib36 – ident: 10.1007/s13311-018-0622-7_bib60 – volume: 13 start-page: 1100 issue: 11 year: 2014 ident: 10.1007/s13311-018-0622-7_bib31 article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70209-1 – year: 2017 ident: 10.1007/s13311-018-0622-7_bib53 article-title: Phase 1, randomized, double-blind, placebo-controlled, single-dose and multiple-dose studies of erenumab in healthy subjects and patients with migraine. publication-title: Clin Pharmacol Ther. – volume: 11 start-page: 1045 issue: 8 year: 2016 ident: 10.1007/s13311-018-0622-7_bib3 article-title: Anti-CGRP monoclonal antibodies in migraine: current perspectives publication-title: Intern Emerg Med. doi: 10.1007/s11739-016-1489-4 – volume: 22 start-page: 54 year: 2002 ident: 10.1007/s13311-018-0622-7_bib18 article-title: CGRP may play a causative role in migraine publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.2002.00310.x – volume: 377 start-page: 2113 year: 2017 ident: 10.1007/s13311-018-0622-7_bib50 article-title: Fremanezumab for the preventive treatment of chronic migraine publication-title: N Engl J Med. doi: 10.1056/NEJMoa1709038 – volume: 37 start-page: 560 issue: 6 year: 2016 ident: 10.1007/s13311-018-0622-7_bib20 article-title: Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents publication-title: Cephalalgia. doi: 10.1177/0333102416650702 – volume: 35 start-page: 478 year: 2015 ident: 10.1007/s13311-018-0622-7_bib2 article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine publication-title: Cephalalgia. doi: 10.1177/0333102414547138 – ident: 10.1007/s13311-018-0622-7_bib40 doi: 10.1001/jamaneurol.2017.3859 – volume: 13 start-page: 857 year: 2014 ident: 10.1007/s13311-018-0622-7_bib25 article-title: Anti-CGRP antibodies: a new approach to migraine prevention publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70126-7 – ident: 10.1007/s13311-018-0622-7_bib43 – volume: 23 start-page: 193 year: 1988 ident: 10.1007/s13311-018-0622-7_bib9 article-title: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system publication-title: Ann Neurol. doi: 10.1002/ana.410230214 – volume: 6 start-page: 573 year: 2010 ident: 10.1007/s13311-018-0622-7_bib10 article-title: CGRP and its receptors provide new insights into migraine pathophysiology publication-title: Nat Rev Neurol. doi: 10.1038/nrneurol.2010.127 – volume: 13 start-page: 885 issue: 9 year: 2014 ident: 10.1007/s13311-018-0622-7_bib39 article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70128-0 – volume: 377 start-page: 553 year: 2017 ident: 10.1007/s13311-018-0622-7_bib62 article-title: Migraine publication-title: N Engl J Med. doi: 10.1056/NEJMcp1605502 – volume: 350 start-page: 1104 year: 2004 ident: 10.1007/s13311-018-0622-7_bib12 article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine publication-title: N Engl J Med. doi: 10.1056/NEJMoa030505 – volume: 155 start-page: 1093 issue: 7 year: 2008 ident: 10.1007/s13311-018-0622-7_bib64 article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat publication-title: Br J Pharmacol. doi: 10.1038/bjp.2008.334 – volume: 34 start-page: 483 issue: 7 year: 2014 ident: 10.1007/s13311-018-0622-7_bib29 article-title: Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program publication-title: Cephalalgia. doi: 10.1177/0333102413517775 – volume: 36 start-page: 1 issue: 1 year: 2005 ident: 10.1007/s13311-018-0622-7_bib27 article-title: Humanized antibodies and their applications publication-title: Methods. doi: 10.1016/j.ymeth.2005.02.001 – ident: 10.1007/s13311-018-0622-7_bib37 – volume: e1 start-page: 88 year: 2017 ident: 10.1007/s13311-018-0622-7_bib58 article-title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the ARISE trial publication-title: J Neurol Neurosurg Psychiatry. – volume: 28 start-page: 183 issue: 2 year: 1990 ident: 10.1007/s13311-018-0622-7_bib15 article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache publication-title: Ann Neurol. doi: 10.1002/ana.410280213 – volume: 37 start-page: 779 year: 2016 ident: 10.1007/s13311-018-0622-7_bib11 article-title: Wiping out CGRP: potential cardiovascular risks publication-title: Trends Pharmacol Sci. doi: 10.1016/j.tips.2016.06.002 – volume: 16 start-page: 425 year: 2017 ident: 10.1007/s13311-018-0622-7_bib57 article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30083-2 – volume: 15 start-page: 347 issue: 4 year: 2016 ident: 10.1007/s13311-018-0622-7_bib14 article-title: AMG 334 CGRP antibody for migraine: time to celebrate? publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(16)00040-5 – volume: 306 start-page: 517 issue: 9 year: 1982 ident: 10.1007/s13311-018-0622-7_bib26 article-title: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody publication-title: N Engl J Med. doi: 10.1056/NEJM198203043060906 – volume: 15 start-page: 382 issue: 4 year: 2016 ident: 10.1007/s13311-018-0622-7_bib55 article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(16)00019-3 – ident: 10.1007/s13311-018-0622-7_bib44 – volume: 346 start-page: 257 issue: 4 year: 2002 ident: 10.1007/s13311-018-0622-7_bib7 article-title: Migraine—current understanding and treatment publication-title: N Engl J Med. doi: 10.1056/NEJMra010917 – volume: 68 start-page: 343 year: 2007 ident: 10.1007/s13311-018-0622-7_bib1 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology doi: 10.1212/01.wnl.0000252808.97649.21 – volume: 8 start-page: 1309 year: 2013 ident: 10.1007/s13311-018-0622-7_bib24 article-title: Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies publication-title: Expert Opin Drug Discov. doi: 10.1517/17460441.2013.826644 – volume: 87 start-page: 41 year: 2016 ident: 10.1007/s13311-018-0622-7_bib48 article-title: TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points publication-title: Neurology. doi: 10.1212/WNL.0000000000002801 – volume: 83 start-page: 958 issue: 11 year: 2014 ident: 10.1007/s13311-018-0622-7_bib23 article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention publication-title: Neurology. doi: 10.1212/WNL.0000000000000771 – ident: 10.1007/s13311-018-0622-7_bib38 – ident: 10.1007/s13311-018-0622-7_bib34 – ident: 10.1007/s13311-018-0622-7_bib41 |
SSID | ssj0053398 |
Score | 2.4564326 |
SecondaryResourceType | review_article |
Snippet | Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs)... |
SourceID | unpaywall pubmedcentral proquest pubmed crossref springer elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 324 |
SubjectTerms | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Biomedical and Life Sciences Biomedicine Calcitonin Calcitonin gene-related peptide Calcitonin Gene-Related Peptide - metabolism Calcitonin Gene-Related Peptide Receptor Antagonists - immunology Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use Central nervous system Clinical trials Clinical Trials as Topic Efficacy Headache Humans Immunoglobulins Migraine Migraine Disorders - drug therapy Migraine Disorders - immunology Migraine Disorders - physiopathology Monoclonal antibodies Neurobiology Neurology Neurosciences Neurosurgery Peptides Review Safety Tolerability Treatment Outcome |
SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVuJx4P0IFGQkTlSpEjt2Em5V1aUCLephK5VT5PgBK6Jk1d0IlV_POImzlMKinmNbsfNl_I1m5huAtyYTNpUlDalJ0UERxoSZTFSoKdexNpnMM1ecPPssjk-Tj2f8bKjjXvlsdx-S7Cz1ptiNsa4GLAsjgR5UehN2uPNPJrBz8OHLpyNvgJHAdC1wkZqwEB0c5oOZf1vkX9fRVbp5NWtyDJ3ehdttvZQXP2RV_XY7Te_D3O-rT0r5vt-uy3318w_Jx2tu_AHcG9gqOejh9RBumPoR3JoN8fjHsESUkb6d5QVpLEEL0aiq6ebU60XZuBzF92TaqHZFmpocykqhCakXNXF612GXimc0OXG5NdoQZNDk5LzBT191xVtktvjqelgYMu_VD57A6fRofngcDj0cQsUTsQ5zy6lEzhdnpXJ9sozjQ0wZquKEJ5qnFEGENsEyIzTPqEYPB70qyZQVjHLJnsKkbmrzHIjVFs2rjWJVikRGNrcZi3RuneJfwpUIIPKfslCDwLnrs1EVG2lmd5IFnmThTrJIA3g3Tln26h7bBlOPj8KXraKhLfDu2TZp1yOpGKzDqqBIrJA4sjwO4M34GP9rF6yRtWnafkzKnNxeAM964I2vSHOBXm6eBJBeguQ4wGmGX35SL7512uE8Z0jhcc09j7XNa23ZxN6I7_-f04trrf0S7tAO2i4Zahcm6_PWvEKety5fD__1L6DwRfA priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VVIJy4E0JFLRInKic2rv22uZWRUQVUqocGqmcrPU-SoS1jlpbqPx6Zv0KpRCEOO9D9vrz7DeamW8A3umEm1jk1KM6RgeFa-0lIpSeopEKlE5Emrji5PkpP1mGn86j8x2Y9rUwTbZ7H5JsaxqcSpOtjtbKHG0K3xhr6sESz-foTcUTHL0Du9xFmUawuzxdHH92rlYSO7XMRnEPmQrz0N9hfWzzd_v86Xa6zT5vJ1EOkdT7cK-2a3H9TRTFT5fV7CGo_jXbHJWvk7rKJ_L7LwqQ_3kOj-BBR2bJcYu-x7Cj7RO4O-_C9U9hjSAkbbfLa1IaggaklEXZrLHVKi9dCuMHMitlfUVKS6aikGhh7MoSJ4ftNZl6WpGFS71RmiDBJovLEpFRNLVdZL66cC0uNDlrxRGewXL28Wx64nUtHjwZhbzyUhNRgZQwSHLp2mhpR5eY1FQGYRSqKKaIMTQZhmmuooQqdIDQ6RJMGs5oJNhzGNnS6hdAjDJofY0fyJyHwjepSZivUuMEAcNI8jH4_afNZKd_7tpwFNlGudmdZoanmbnTzOIxvB-WrFvxj22TaY-XrK9qRTuc4dW0bdFBj6ysMx5XGUXehbySpcEY3g7D-Nu7WI6wuqzbOTFzanxj2G-BODwiTTk6wWk4hvgGRIcJTlL85ohdfWmkxaOUIcPHPQ977G0ea8tLHA54__s5vfyn2a9gjzbwdrlSBzCqLmv9Gmlglb_pfvMfxuJRZw priority: 102 providerName: Unpaywall |
Title | The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1878747923015647 https://link.springer.com/article/10.1007/s13311-018-0622-7 https://www.ncbi.nlm.nih.gov/pubmed/29616494 https://www.proquest.com/docview/2021172391 https://www.proquest.com/docview/2021731341 https://pubmed.ncbi.nlm.nih.gov/PMC5935651 https://link.springer.com/content/pdf/10.1007/s13311-018-0622-7.pdf |
UnpaywallVersion | publishedVersion |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1878-7479 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: AKRWK dateStart: 20070101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1878-7479 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: AFBBN dateStart: 20040101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central (Free e-resource, activated by CARLI) customDbUrl: eissn: 1878-7479 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: RPM dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1878-7479 dateEnd: 20231031 omitProxy: true ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: 7X7 dateStart: 20070101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1878-7479 dateEnd: 20231031 omitProxy: true ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: BENPR dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1878-7479 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: AGYKE dateStart: 20040101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1878-7479 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053398 issn: 1878-7479 databaseCode: U2A dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9swEBdbC_t4GPvq5q0rGuxpRWBLtmzvZWQlWVlICKVh6ZOR9bEFjJ01CaP__e78lZWy7MkEScH23Um_8939jpAPNpEuVjln3MbgoEhrWaJCzQyPTGBsotIEi5MnU3k-D78tokX7wW3dplV2e2K9UZtK4zdydNIDOGxFGnxe_WLYNQqjq20LjfvkMACoglodL3qHC5BM3QsXMIpg4OmILqpZl84JUVeUJcyX4I_F_zqX7uLOu-mTfQz1MXm4LVfq5rcqir-OqdFT8qTFl3TQKMQzcs-Wz8mDSRtBf0FWoBe0aUB5QytHwaYrXVT1mnKzzCvMKvxER5XermlV0jNVaDD6cllSZKhmdfKcNXSG2TDGUsC8dHZdgbCKutyKTpY_sOuEpZcNX8FLMh8NL8_OWdt1gekolBuWuogrQGlBkmvsbGURwQhtuQ7CKDRRzEHsYMVOWGmihBvwScAPUkI7KXikxBE5KKvSvibUGQcbovMDnctQ-S51ifBN6pCjL4y09IjfvfNMt5Tk2BmjyHZkyiimDMSUoZiy2CMf-yWrho9j32TeCTLrCk1ha8zgtNi36LgTedba8zrbaZ9H3vfDYIkYXlGlrbbNnFggQZ5HXjUa0t8iTyX4pWnokfiW7vQTkOX79ki5_FmzfUepANAN_3naadnutvY8xGmviP9_T2_2P_Jb8ojXhoL5SsfkYHO9te8Aim3yk9reTsjh4OvVeIjX8cX3MVy_DKezCxid8wH8mk9ng6s_vos0Dg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIlF6QLwKLgUWCS5UluxdP5EQQoUopU3VQyrlZtb7gEiWHZpEVf4Uv5EZv0JVEU49e3fl9Xw7-43nBfDWJJGNZc5dbmI0UCJj3EQGytU81L42iUwTSk4enUXDi-DbJJxswe8uF4bCKjudWCtqXSn6R05Guo-XrUj9T7NfLnWNIu9q10KjgcWJWV2hyTb_ePwF5fuO88HX8dHQbbsKuCoMooWb2pBLZCF-kivq3GTohhbKcOUHYaDDmOO2EKVWmEiHCdfIuZHnS6FsJHgoBa57B-4GwguoVn886Q08ZE51713kRMJFy0p0XtQ6VU-IOoMtcb0I7b_4X_fgTZ57M1yz99nuws6ynMnVlSyKv67FwUN40PJZ9rkB4CPYMuVjuDdqPfZPYIY4ZE3DyxWrLEMdUqmiqueUi2leURTjBzao1HLOqpIdyUKhkimnJaOK2G4drGc0O6foG20Ycmx2flkhOIo6vYuNpj-oy4Vh46Y-wlO4uBV57MF2WZXmOTCrLSpg6_kqjwLp2dQmwtOppZqAQagiB7zum2eqLYFOnTiKbF28mcSUoZgyElMWO_C-nzJr6n9sGsw7QWZdYiuq4gxvp02TDjqRZ63-mGdrtDvwpn-MJ5_cObI01bIZEwsqyOfAswYh_SvyNEI7OA0ciK9hpx9AVcWvPymnP-vq4mEqkOTjmocdytavtWEThz0Q__-d9jdv-TXsDMej0-z0-OzkBdzn9aGhWKkD2F5cLs1LpIGL_FV99hh8v-3D_gfK_Gf4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIhU4IN4YCiwSXKgs7F0_kRBCLVFLSZVDK-VmNvuASJYdmkRV_hq_jpn1I1QV4dSzd1dez7ez33heAG9MlthUTrjPTYoGSmKMn8lI-ZrHOtQmk3lGycnDk-TwLPo6jsdb8LvLhaGwyk4nOkWta0X_yMlID_GyFXn43rZhEaODwafZL586SJGntWun0UDk2Kwu0Hybfzw6QFm_5Xzw5XT_0G87DPgqjpKFn9uYS2QkYTZR1MXJ0G0tlOEqjOJIxynHLSJirTCJjjOukX8j55dC2UTwWApc9wbcTEUkKJwsHffGHrIo14cX-ZHw0coSnUfVpe0J4bLZMj9I0BZM_3UnXuW8V0M3e__tHbi1rGZydSHL8q8rcnAP7rbcln1uwHgftkz1AHaGrff-IcwQk6xpfrlitWWoT2pV1m5OtZhOaopo_MAGtVrOWV2xfVkqVDjVtGJUHdt3gXtGsxFF4mjDkG-z0XmNQCldqhcbTn9QxwvDTptaCY_g7Frk8Ri2q7oyT4FZbVEZ2yBUkySSgc1tJgKdW6oPGMUq8SDovnmh2nLo1JWjLNaFnElMBYqpIDEVqQfv-imzphbIpsG8E2TRJbmiWi7wpto0abcTedHqknmxRr4Hr_vHqAXItSMrUy-bMamg4nwePGkQ0r8izxO0ifPIg_QSdvoBVGH88pNq-tNVGo9zgYQf19zrULZ-rQ2b2OuB-P_v9Gzzll_BDh7z4tvRyfFzuM3dmaGwqV3YXpwvzQtkhIvJS3f0GHy_7rP-Bx0tbDM |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VVIJy4E0JFLRInKic2rv22uZWRUQVUqocGqmcrPU-SoS1jlpbqPx6Zv0KpRCEOO9D9vrz7DeamW8A3umEm1jk1KM6RgeFa-0lIpSeopEKlE5Emrji5PkpP1mGn86j8x2Y9rUwTbZ7H5JsaxqcSpOtjtbKHG0K3xhr6sESz-foTcUTHL0Du9xFmUawuzxdHH92rlYSO7XMRnEPmQrz0N9hfWzzd_v86Xa6zT5vJ1EOkdT7cK-2a3H9TRTFT5fV7CGo_jXbHJWvk7rKJ_L7LwqQ_3kOj-BBR2bJcYu-x7Cj7RO4O-_C9U9hjSAkbbfLa1IaggaklEXZrLHVKi9dCuMHMitlfUVKS6aikGhh7MoSJ4ftNZl6WpGFS71RmiDBJovLEpFRNLVdZL66cC0uNDlrxRGewXL28Wx64nUtHjwZhbzyUhNRgZQwSHLp2mhpR5eY1FQGYRSqKKaIMTQZhmmuooQqdIDQ6RJMGs5oJNhzGNnS6hdAjDJofY0fyJyHwjepSZivUuMEAcNI8jH4_afNZKd_7tpwFNlGudmdZoanmbnTzOIxvB-WrFvxj22TaY-XrK9qRTuc4dW0bdFBj6ysMx5XGUXehbySpcEY3g7D-Nu7WI6wuqzbOTFzanxj2G-BODwiTTk6wWk4hvgGRIcJTlL85ohdfWmkxaOUIcPHPQ977G0ea8tLHA54__s5vfyn2a9gjzbwdrlSBzCqLmv9Gmlglb_pfvMfxuJRZw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Biology+of+Monoclonal+Antibodies%3A+Focus+on+Calcitonin+Gene-Related+Peptide+for+Prophylactic+Migraine+Therapy&rft.jtitle=Neurotherapeutics&rft.au=Raffaelli%2C+Bianca&rft.au=Reuter%2C+Uwe&rft.date=2018-04-01&rft.pub=Springer+Nature+B.V&rft.issn=1933-7213&rft.eissn=1878-7479&rft.volume=15&rft.issue=2&rft.spage=324&rft.epage=335&rft_id=info:doi/10.1007%2Fs13311-018-0622-7&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1878-7479&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1878-7479&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1878-7479&client=summon |